David Lewis
Stock Analyst at Morgan Stanley
(2.68)
# 2,036
Out of 4,711 analysts
281
Total ratings
65.47%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $107 → $117 | $114.23 | +2.42% | 23 | Oct 17, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $266.57 | +12.54% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $227.68 | +20.78% | 23 | Oct 11, 2022 | |
| NVRO Nevro | Maintains: Equal-Weight | $55 → $54 | $3.79 | +1,324.80% | 12 | Aug 4, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $80.04 | +13.69% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $50 → $48 | $1.21 | +3,866.94% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $29.50 | +238.98% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $61.70 | -75.69% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $6.15 | +387.80% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $71.65 | +4.68% | 11 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $45 | $18.70 | +140.64% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $75.44 | -20.47% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $82.63 | -0.76% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $178.16 | +141.92% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $81.03 | +90.05% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $13.25 | +201.89% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $74.81 | +80.46% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $364.60 | -23.20% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $524.43 | -45.66% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $10.67 | +78.07% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $90.39 | +3.99% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $84.76 | -6.80% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $107.12 | +68.04% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $144.47 | +29.44% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $16.08 | +179.85% | 5 | Dec 15, 2020 |
Abbott Laboratories
Oct 17, 2024
Maintains: Equal-Weight
Price Target: $107 → $117
Current: $114.23
Upside: +2.42%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $266.57
Upside: +12.54%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $227.68
Upside: +20.78%
Nevro
Aug 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $54
Current: $3.79
Upside: +1,324.80%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $80.04
Upside: +13.69%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $50 → $48
Current: $1.21
Upside: +3,866.94%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $29.50
Upside: +238.98%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $61.70
Upside: -75.69%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $6.15
Upside: +387.80%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $71.65
Upside: +4.68%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $18.70
Upside: +140.64%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $75.44
Upside: -20.47%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $82.63
Upside: -0.76%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $178.16
Upside: +141.92%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $81.03
Upside: +90.05%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $13.25
Upside: +201.89%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $74.81
Upside: +80.46%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $364.60
Upside: -23.20%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $524.43
Upside: -45.66%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $10.67
Upside: +78.07%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $90.39
Upside: +3.99%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $84.76
Upside: -6.80%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $107.12
Upside: +68.04%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $144.47
Upside: +29.44%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $16.08
Upside: +179.85%